Top Tweets for #ACScancerchat
What promising results have we seen with antibody drug conjugates🧪in the treatment of urothelial cancer, specifically enfortumab vedotin and sacituzumab govitecan #ACSCancerChat
@weoncologists @drfrankiejs @OncoAlert @VivekSubbiah @WalterStadler5 @apolo_andrea @PGrivasMDPhD @shilpaonc @neerajaiims @DrChoueiri @TiansterZhang @amerseburger @nataliagandur @Martin_AngelMD @DrYukselUrun EV SG and DV all going fast. We’re expecting EV and Pembro R3 results in the 1st line and MIBC space in the not too distant future . SG vs chemo in platinum refractory disease is v. exciting. I’d like to see combos of these agents @DrChoueiri DV phase II data also #ACScancerchat
On behalf of @OncoAlert 🚨
Thank you #ACSCancerChat and our friends at @JournalCancer !!!
Amazing conversations @drfrankiejs @tompowles1 , Dr. Matthew Young, @VivekSubbiah
@WalterStadler5
@weoncologists @drfrankiejs @OncoAlert @VivekSubbiah @WalterStadler5 @apolo_andrea @PGrivasMDPhD @shilpaonc @neerajaiims @DrChoueiri @TiansterZhang @amerseburger @nataliagandur @Martin_AngelMD @DrYukselUrun EV SG and DV all going fast. We’re expecting EV and Pembro R3 results in the 1st line and MIBC space in the not too distant future . SG vs chemo in platinum refractory disease is v. exciting. I’d like to see combos of these agents @DrChoueiri DV phase II data also #ACScancerchat
Last #ACSCancerChat question @drfrankiejs @tompowles1 & Dr. Young 🙏
What promising results have we seen with antibody drug conjugates🧪in the treatment of urothelial cancer, specifically enfortumab vedotin and sacituzumab govitecan❓
@OncoAlert 🚨 @VivekSubbiah @WalterStadler5
@JournalCancer @QMBCI @tompowles1 @WalterStadler5 @KidneyCancer @DrChoueiri @AmerCancerCEO @montypal @ACS_Research @advocatekidneys @RamalingamMD @VivekSubbiah @billdahutmd @nataliagandur mCSPC what is the role of triplet therapy? (ADT + Docetaxel + ARAT) #ACSChemochat
Looks like our hour is drawing to a close. Any last-minute thoughts from our panelists or members of our audience? #ACSCancerChat
Is there a role for discontinuing immunotherapy in patients with an excellent response, if so when? #ACSCancerChat @tompowles1 @drfrankiejs
What advancements have been made in tx of metastatic castrate-sensitive #ProstateCancer ✅Specially regarding3⃣triplet therapy
@OncoAlert 🚨 #ACSCancerChat
@weoncologists @drfrankiejs @OncoAlert @VivekSubbiah @WalterStadler5 I think pateint selection here is going to be really important - also HSPC PARP studies and the new androgen degraders are super exciting.
@VivekSubbiah @JournalCancer @QMBCI @tompowles1 @WalterStadler5 @KidneyCancer @DrChoueiri @AmerCancerCEO @montypal @ACS_Research @advocatekidneys @RamalingamMD @billdahutmd @nataliagandur The results of the work on nectin4 has not been consistent. The result relies on a H score (based on IHC). Because majority of bladder ca express nectin4 to some degree, it’s not been a major focus. A recent publication from Germany suggests more work is required #ACScancerchat
@tompowles1 @JournalCancer @QMBCI @drfrankiejs @WalterStadler5 @KidneyCancer @DrChoueiri @AmerCancerCEO @montypal @ACS_Research @advocatekidneys @RamalingamMD @billdahutmd @nataliagandur @NEJM Interesting study was also published in @TheLancetOncol Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study @DrChoueiri #ACSCancerChat https://t.co/ZKEw0O5GqX
@tompowles1 @JournalCancer @QMBCI @drfrankiejs @WalterStadler5 @KidneyCancer @DrChoueiri @AmerCancerCEO @montypal @ACS_Research @advocatekidneys @RamalingamMD @billdahutmd @nataliagandur Here is the paper on Belzutifan "Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease" @NEJM @JournalCancer #ACScancerchat
https://t.co/TNXnHmojSG
@JournalCancer @tompowles1 Dr Matthew Young @BartsECMC “EV302: 1L EV and pembro. The most recent chemotherapy and nivolumab trial warrants close attention. Also looking forward to data from new Antibody drug conjugates in bladder ca (RC-48 trialling Disitimab Vedotin - phase II ongoing) #ACScancerchat”
What are current challenges & limitations in the use of immune checkpoint inhibitors🧪 in the adjuvant setting for renal cell carcinoma #KidneyCancer ?
#ACScancerchat @OncoAlert 🚨
@weoncologists @tompowles1 @OncoAlert @VivekSubbiah @WalterStadler5 Challenges are 1)not selecting patients 2)risk of 10% life changing toxicity and 3) no overall survival benefit yet. Patients need to be aware of these limitations #ACScancerchat
I'll put my bet on "yes" but just barely since everolimus is not much better than a toxic placebo. #ACSCancerChat
@JournalCancer @QMBCI @drfrankiejs @WalterStadler5 @KidneyCancer @DrChoueiri @AmerCancerCEO @montypal @ACS_Research @advocatekidneys @RamalingamMD @VivekSubbiah @billdahutmd @nataliagandur HIF2a is an important new target In RCC. Belzutifan looks really good in VHL driven disease and looks like a great combination partner. Most exciting R3 in the near future in RCC is belzutifan vs everolimus IMO. Do you think it will be possible for OS? #ACScancerchat
Quick #ACSCancerChat question
@drfrankiejs @tompowles1 & Dr. Young
What advancements have been made in tx of metastatic castrate-sensitive #ProstateCancer
✅Specially regarding3⃣triplet therapy🧪& tx of high-risk nonmetastatic disease
@OncoAlert @VivekSubbiah @WalterStadler5
@JournalCancer @QMBCI @drfrankiejs @WalterStadler5 @KidneyCancer @DrChoueiri @AmerCancerCEO @montypal @ACS_Research @advocatekidneys @RamalingamMD @VivekSubbiah @billdahutmd @nataliagandur HIF2a is an important new target In RCC. Belzutifan looks really good in VHL driven disease and looks like a great combination partner. Most exciting R3 in the near future in RCC is belzutifan vs everolimus IMO. Do you think it will be possible for OS? #ACScancerchat
@weoncologists @tompowles1 @OncoAlert @VivekSubbiah @WalterStadler5 Challenges are 1)not selecting patients 2)risk of 10% life changing toxicity and 3) no overall survival benefit yet. Patients need to be aware of these limitations #ACScancerchat
@JournalCancer @tompowles1 The introduction of adjuvant therapy in renal cancer, triplet therapy in prostate cancer and EV/Pembro combination in bladder cancer. These have all had a major impact on practice. #ACSCancerchat
Quick #ACSCancerChat question to @drfrankiejs,
@tompowles1, and Dr. Matthew Young.
What are current challenges & limitations in the use of immune checkpoint inhibitors🧪 in the adjuvant setting for renal cell carcinoma #KidneyCancer ?
@OncoAlert 🚨 @VivekSubbiah @WalterStadler5
.@drfrankiejs @tompowles1: In your expert opinion, which advance would you consider to be the biggest development in genitourinary cancer treatment? #ACSCancerChat
Last Seen Hashtags on Sotwe
exny()*+filter:native_video
Seen from United Kingdom
cumpilation men
口交
Seen from United States
girls () +filter:native_video
Seen from United Kingdom
rashmer si
Seen from Italy
outdoor sục cặc
Seen from Vietnam
memek artis
Seen from Indonesia
yağmurŞimşek
Seen from Turkey
braveheart
Seen from United States
angelawhite anal
Seen from Turkey
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
240.3M followers
Barack Obama
@barackobama
119.3M followers
Donald J. Trump
@realdonaldtrump
111.6M followers
Cristiano Ronaldo
@cristiano
109.6M followers
Narendra Modi
@narendramodi
106.9M followers
Rihanna
@rihanna
97.4M followers
NASA
@nasa
92.1M followers
Justin Bieber
@justinbieber
90.7M followers
KATY PERRY
@katyperry
87.2M followers
Taylor Swift
@taylorswift13
81M followers
Lady Gaga
@ladygaga
72.5M followers
Kim Kardashian
@kimkardashian
69.5M followers
Virat Kohli
@imvkohli
69.1M followers
YouTube
@youtube
68.6M followers
Bill Gates
@billgates
63.6M followers
The Ellen Show
@theellenshow
62.5M followers
CNN
@cnn
61.9M followers
Neymar Jr
@neymarjr
61.8M followers
X
@x
60.9M followers
Selena Gomez
@selenagomez
60.3M followers